PL4125903T3 - Sposoby rozpoczynania podawania leczenia arypiprazolem - Google Patents
Sposoby rozpoczynania podawania leczenia arypiprazolemInfo
- Publication number
- PL4125903T3 PL4125903T3 PL21720012.0T PL21720012T PL4125903T3 PL 4125903 T3 PL4125903 T3 PL 4125903T3 PL 21720012 T PL21720012 T PL 21720012T PL 4125903 T3 PL4125903 T3 PL 4125903T3
- Authority
- PL
- Poland
- Prior art keywords
- aripiprazole
- treatments
- methods
- dose initiation
- initiation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003544P | 2020-04-01 | 2020-04-01 | |
| PCT/JP2021/014194 WO2021201239A1 (en) | 2020-04-01 | 2021-04-01 | Methods for dose initiation of aripiprazole treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4125903T3 true PL4125903T3 (pl) | 2025-02-03 |
Family
ID=75581573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21720012.0T PL4125903T3 (pl) | 2020-04-01 | 2021-04-01 | Sposoby rozpoczynania podawania leczenia arypiprazolem |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US20220160621A1 (https=) |
| EP (3) | EP4125903B1 (https=) |
| JP (4) | JP7584535B2 (https=) |
| KR (3) | KR102732030B1 (https=) |
| CN (3) | CN115397420A (https=) |
| AU (2) | AU2021245713A1 (https=) |
| BR (2) | BR112022018647A2 (https=) |
| CA (3) | CA3136727A1 (https=) |
| ES (1) | ES2995466T3 (https=) |
| HR (1) | HRP20241574T1 (https=) |
| HU (1) | HUE069157T2 (https=) |
| MX (2) | MX2022012353A (https=) |
| PL (1) | PL4125903T3 (https=) |
| TW (3) | TWI865760B (https=) |
| WO (2) | WO2021201238A1 (https=) |
| ZA (1) | ZA202210633B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050032811A1 (en) * | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| TWI865760B (zh) | 2020-04-01 | 2024-12-11 | 日商大塚製藥股份有限公司 | 阿立哌唑注射用製劑之投予方法 |
| US20250387321A1 (en) | 2023-03-17 | 2025-12-25 | Otsuka Pharmaceutical Co., Ltd. | Methods of dispersing aripiprazole injectable preparations |
| AU2024263986A1 (en) * | 2023-04-26 | 2025-10-09 | Otsuka Pharmaceutical Co., Ltd. | Dose initiation for schizophrenia or bipolar i disorder treatment with aripiprazole |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| ATE411797T2 (de) * | 2003-10-23 | 2008-11-15 | Otsuka Pharma Co Ltd | Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren |
| MX2009014115A (es) | 2007-06-25 | 2010-04-21 | Otsuka Pharma Co Ltd | Microesferas que tienen estructura de nucleo/corteza. |
| JOP20200109A1 (ar) * | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| US10525057B2 (en) | 2013-09-24 | 2020-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
| JP2020520380A (ja) * | 2017-05-16 | 2020-07-09 | ボウ リバー エルエルシー | 処置法 |
| EP3761983A1 (en) * | 2018-03-05 | 2021-01-13 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| CN108498456B (zh) | 2018-05-16 | 2021-01-01 | 丽珠医药集团股份有限公司 | 一种阿立哌唑缓释微球及其制备方法 |
| CN110327296B (zh) | 2019-08-06 | 2021-10-22 | 深圳市泛谷药业股份有限公司 | 一种阿立哌唑长效注射制剂及其制备方法 |
| TWI865760B (zh) | 2020-04-01 | 2024-12-11 | 日商大塚製藥股份有限公司 | 阿立哌唑注射用製劑之投予方法 |
-
2021
- 2021-04-01 TW TW110112186A patent/TWI865760B/zh active
- 2021-04-01 JP JP2022559751A patent/JP7584535B2/ja active Active
- 2021-04-01 WO PCT/JP2021/014192 patent/WO2021201238A1/en not_active Ceased
- 2021-04-01 US US17/594,292 patent/US20220160621A1/en not_active Abandoned
- 2021-04-01 CN CN202180025911.8A patent/CN115397420A/zh active Pending
- 2021-04-01 CN CN202180026022.3A patent/CN115379842A/zh active Pending
- 2021-04-01 CA CA3136727A patent/CA3136727A1/en active Pending
- 2021-04-01 PL PL21720012.0T patent/PL4125903T3/pl unknown
- 2021-04-01 EP EP21720012.0A patent/EP4125903B1/en active Active
- 2021-04-01 BR BR112022018647A patent/BR112022018647A2/pt unknown
- 2021-04-01 ES ES21720012T patent/ES2995466T3/es active Active
- 2021-04-01 TW TW110112185A patent/TWI906279B/zh active
- 2021-04-01 KR KR1020227037401A patent/KR102732030B1/ko active Active
- 2021-04-01 AU AU2021245713A patent/AU2021245713A1/en active Pending
- 2021-04-01 KR KR1020227037400A patent/KR20220161402A/ko active Pending
- 2021-04-01 MX MX2022012353A patent/MX2022012353A/es unknown
- 2021-04-01 TW TW113142852A patent/TW202523329A/zh unknown
- 2021-04-01 US US17/907,583 patent/US20230129919A1/en not_active Abandoned
- 2021-04-01 CA CA3163321A patent/CA3163321C/en active Active
- 2021-04-01 CA CA3212191A patent/CA3212191A1/en active Pending
- 2021-04-01 AU AU2021248212A patent/AU2021248212A1/en active Pending
- 2021-04-01 CN CN202411916296.1A patent/CN119792290A/zh active Pending
- 2021-04-01 HR HRP20241574TT patent/HRP20241574T1/hr unknown
- 2021-04-01 KR KR1020247038040A patent/KR20240165486A/ko active Pending
- 2021-04-01 EP EP24205231.4A patent/EP4467194A3/en active Pending
- 2021-04-01 EP EP21720011.2A patent/EP3941470A1/en active Pending
- 2021-04-01 JP JP2022559750A patent/JP7733000B2/ja active Active
- 2021-04-01 MX MX2022012354A patent/MX2022012354A/es unknown
- 2021-04-01 BR BR112022018721A patent/BR112022018721A2/pt unknown
- 2021-04-01 WO PCT/JP2021/014194 patent/WO2021201239A1/en not_active Ceased
- 2021-04-01 HU HUE21720012A patent/HUE069157T2/hu unknown
-
2022
- 2022-09-26 ZA ZA2022/10633A patent/ZA202210633B/en unknown
-
2023
- 2023-03-15 US US18/184,135 patent/US20230225962A1/en not_active Abandoned
-
2024
- 2024-06-03 US US18/732,392 patent/US20240374506A1/en active Pending
- 2024-11-05 JP JP2024193628A patent/JP2025020306A/ja active Pending
-
2025
- 2025-08-21 JP JP2025137577A patent/JP2025176037A/ja active Pending
- 2025-10-08 US US19/352,541 patent/US20260034053A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4125903T3 (pl) | Sposoby rozpoczynania podawania leczenia arypiprazolem | |
| IL288523A (en) | Compounds for the treatment of pd-l1 diseases | |
| GB202020573D0 (en) | Novel methods of therapy | |
| EP4010081A4 (en) | POLYTHERAPY FOR THE TREATMENT OF CANCER | |
| IL282643A (en) | Soft combinations for the treatment of hematological diseases | |
| IL255898A (en) | Converted pyrazole and pyrrole compounds and methods of using them to prevent the onset of conversion and treat related diseases | |
| GB202020572D0 (en) | Novel methods of therapy | |
| IL285050A (en) | Administering PD-1 inhibitors for the treatment of skin cancer | |
| KR102527404B9 (ko) | 인슐린 투여량 조절 방법 | |
| GB202006072D0 (en) | Method of selecting patients for treatment with cmbination therapy | |
| IL290892A (en) | Methods for treating vascular diseases | |
| IL289201A (en) | Compounds for the treatment of cancer | |
| IL287250A (en) | treatment method | |
| GB201908565D0 (en) | Method of stratifying subjects into sub-groups for therapeutic treatment | |
| IL285458A (en) | Combined therapy for the treatment of b-cell malignancies | |
| IL288415A (en) | Combinations and methods for the treatment of hemochromatosis | |
| SG11202109025XA (en) | Combinations of iadademstat for cancer therapy | |
| GB201812861D0 (en) | Methods of administering therapy | |
| EP3585434A4 (en) | METHOD OF PHOTOCHEMICAL TREATMENT FOR WOUND HEALING | |
| IL321323A (en) | Methods for administering blomosodil for the treatment of multiple myeloma | |
| GB202020570D0 (en) | Novel methods of therapy | |
| GB202118007D0 (en) | Methods of treatment | |
| GB202118011D0 (en) | Methods of treatment | |
| GB202118006D0 (en) | Methods of treatment | |
| IL312899A (en) | Combined treatment for cancer |